葡萄糖剥夺的肿瘤微环境激活 AMP 活化蛋白激酶驱动过继转移的 T 辅助 9 细胞衰老
Glucose-deprived tumor microenvironment activates AMP-activated protein kinase to drive adoptively transferred T helper 9 cell senescence.
辅助性T细胞9(Th9)细胞在针对实体瘤的过继细胞治疗(ACT)中显示出前景。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Navigating chimeric antigen receptor-engineered natural killer cells as drug carriers via three-dimensional mapping of the tumor microenvironment.
Navigating chimeric antigen receptor-engineered natural killer cells as drug carriers via three-dimensional mapping of the tumor microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)修饰的自然杀伤(NK)细胞是有前景的癌症免疫治疗药物,但肿瘤微环境(TME)中的复杂屏障会限制 CAR-NK 细胞治疗实体瘤的疗效及迁移能力。
我们开发了一种新策略,利用活的 CAR-NK 细胞作为载体,将抗癌药物特异性递送至肿瘤部位。我们还介绍一种时间序列成像方法,在活体小鼠模型和三维(3D)组织切片培养中,使用双光子显微镜评估 CAR-NK 细胞的疗效和肿瘤特异性。
结果表明,在体外和体内肿瘤模型中,CAR-NK 细胞与光敏化学物质联合使用可增强抗肿瘤免疫。此外,我们成功使用非侵入性活体双光子显微镜成像,观察了载药 CAR-NK 细胞在深部 TME 中的迁移、浸润和积聚。研究结果强调,可通过双光子显微镜方法在活体内监测 CAR-NK 细胞的肿瘤浸润。
总之,本研究成功将 CAR-NK 细胞用作药物载体,为癌症治疗中细胞疗法与小分子疗法联合应用铺平了道路。此外,我们的 3D 平台为评估 CAR 细胞在实体瘤中的行为提供了有价值的工具,有助于结合临床成像方法开发和优化免疫治疗策略。
Chimeric antigen receptor (CAR)-modified natural killer (NK) cells are recognized as promising immunotherapeutic agents for cancer treatment.
However, the efficacy and trafficking of CAR-NK cells in solid tumors are hindered by the complex barriers present in the tumor microenvironment (TME).
We have developed a novel strategy that utilizes living CAR-NK cells as carriers to deliver anticancer drugs specifically to the tumor site.
We also introduce a time-lapse method for evaluating the efficacy and tumor specificity of CAR-NK cells using a two-photon microscope in live mouse models and three-dimensional (3D) tissue slide cultures.
Our results demonstrate that CAR-NK cells exhibit enhanced antitumor immunity when combined with photosensitive chemicals in both in vitro and in vivo tumor models.
Additionally, we have successfully visualized the trafficking, infiltration, and accumulation of drug-loaded CAR-NK cells in deeply situated TME using non-invasive intravital two-photon microscopy.
Our findings highlight that tumor infiltration of CAR-NK cells can be intravitally monitored through the two-photon microscope approach.
In conclusion, our study demonstrates the successful integration of CAR-NK cells as drug carriers and paves the way for combined cellular and small-molecule therapies in cancer treatment. Furthermore, our 3D platform offers a valuable tool for assessing the behavior of CAR cells within solid tumors, facilitating the development and optimization of immunotherapeutic strategies with clinical imaging approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。